United States

Analyst Research Report Snapshot


Biotec Pharmacon ASA (BIOTEC) - Financial Analysis Review






17 Jun 2014





Companies referenced:


Available for Immediate Download

Biotec Pharmacon ASA (BIOTEC) - Financial Analysis Review Summary Biotec Pharmacon ASA (Biotec Pharmacon) is a bio-pharmaceutical company. It researches, develops, manufactures and markets immune modulating compounds and marine enzymes that are used in molecular biology. The company operates through two operating subsidiaries, namely, Biotec BetaGlucans AS and ArcticZymes AS. Its Biotec BetaGlucans AS develops and manufactures immune modulating compounds for the human health sectors. It conducts research on various proprietary beta-1,3/1,6-glucan products. GlobalData's Biotec Pharmacon ASA (BIOTEC) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Biotec Pharmacon ASA Key Recent Developments: May 06, 2013: Biotec Pharmacon Reports Revenue Of NOK5.9m In Q1 2013 Feb 28, 2013: ArcticZymes Receives Acceptance For Patent Application Covering Its Heat-labile DNase Product In South Africa Feb 18, 2013: ArcticZymes Receives NOK5m Research Grant From Research Council Of Norway Feb 14, 2013: Biotec Pharmacon Reports Revenue Of NOK21.5m In 2012 This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.